Successful treatment of a non‐small‐cell lung cancer patient harboring HIP1‐ALK (H28:A20) and CTNNB1 p.S45del with alectinib

Abstract This is the first case report of a non‐small‐cell lung cancer (NSCLC) patient harboring HIP1‐ALK (H28:A20) and CTNNB1 p.S45del treated with first‐line alectinib. Approximately 5% of NSCLC patients are reported to have anaplastic lymphoma kinase (ALK) rearrangements, and among these EML4‐ALK...

Cijeli opis

Bibliografski detalji

Glavni autori:	Vito Longo, Francesco Pesola, Rosanna Lacalamita, Annamaria Catino, Michele Montrone, Ilaria Marech, Pamela Pizzutilo, Elisabetta Sara Montagna, Stefania Tommasi, Domenico Galetta
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2024-11-01
Serija:	Thoracic Cancer
Teme:	HIP1‐ALK (H28:A20) CTNNB1 p.S45del Alectinib
Online pristup:	https://doi.org/10.1111/1759-7714.15397
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!